Myocardial injury is increased in the aged heart during ischemia and reperfusion. Aging decreases oxidative metabolism in interfibrillar mitochondria (IFM) located between the myofibrils. We asked whether reversal of aging defects in IFM before ischemia would decrease injury in the aged heart following ischemia and reperfusion. Treatment with acetylcarnitine (AcCN) increases the activity of cytochrome oxidase in the aged heart. Aged (24 months) and adult (6 months) Fischer 344 rats were treated with AcCN (300 mg/kg i.p. 3 h before excision of the heart) or served as controls. AcCN restored oxidative phosphorylation and the activity of complexes III and IV in IFM from aged hearts to rates present in adults. Isolated hearts underwent 25 min global ischemia and 30 min reperfusion without additional treatment. Contractile recovery during reperfusion improved in hearts from AcCN-treated aged rats compared to aged controls and were similar to adults in recovery. AcCN-treated aged hearts sustained less damage, indicated by decreased lactate dehydrogenase (LDH) release during reperfusion. AcCN treatment did not alter functional recovery or LDH release in adults. Restoration of mitochondrial function in the aged heart before ischemia was accompanied by enhanced contractile recovery and decreased tissue injury following ischemia and reperfusion.-Lesnefsky, E. J., He, D., Moghaddas, S., Hoppel, C. L. Reversal of mitochondrial defects before ischemia protects the aged heart. FASEB J. 20, E840 -E845 (2006) 
The aged heart sustains greater damage during ischemia and reperfusion in experimental models (1) (2) (3) (4) (5) and elderly patients (6) . Mitochondria are key participants (1, 3, 7) in several mechanisms reported to enhance cardiac injury in the aged heart during ischemia and reperfusion (8) , including oxidative damage (4) , myocyte calcium accumulation (1) , and apoptosis (5) . In the aged heart, ischemic damage to mitochondria is superimposed on preexisting aging-induced defects in mitochondrial oxidative metabolism , (9 -11) . We evaluated whether an intervention with the potential to improve mitochondrial function in the aged heart before ischemia could decrease myocardial injury during subsequent ischemia and reperfusion.
Cardiac mitochondria exist in two functionally distinct populations: subsarcolemmal mitochondria (SSM) lie beneath the plasma membrane; interfibrillar mitochondria (IFM) are located between the myofibrils (12) (13) (14) . Aging decreases oxidative function only in IFM whereas SSM are unaffected (13) . Aging decreases the activity of electron transport complexes III (9) and IV (13, 15) in IFM. If the aging defects in mitochondrial respiration could be diminished or removed, would the aged heart now function as the adult heart and sustain similar damage as the adult heart during ischemia and reperfusion? Treatment with acetylcarnitine was previously reported to restore aging-induced decreases in complex IV activity in the heart (15) . We used acetylcarnitine to ask whether aging-induced decreases in mitochondrial respiration could be improved. In the current study, acetylcarnitine treatment improved rates of oxidative phosphorylation in mitochondria from aged hearts. Acetylcarnitine treatment did not improve contractile recovery or decrease lactate dehydrogenase release following ischemia in the adult heart. Acetylcarnitine treatment to restore mitochondrial function in the aged heart before ischemia provides an experimental model to test the hypothesis that aging-induced mitochondrial defects in respiration are a mechanism of the enhanced damage sustained by the aged heart during ischemia and reperfusion.
MATERIALS AND METHODS
Adult (6 months) and elderly (24 months) male Fisher 344 rats were obtained from the National Institute of Aging colony (Harlan Sprague Dawley, Inc., Indianapolis, IN, USA). Rats received heparin (500 U/kg, i.p.), were anesthetized with pentobarbital (100 mg/kg, i.p.), and hearts were rapidly excised, perfused in the Langendorff mode with modified Krebs-Henseleit buffer (NaCl 115 mM, KCl 4 mM, MgSO 4 ⅐7H 2 O 1.1 mM, KH 2 PO 4 0.9 mM, NaHCO 3 22 mM, CaCl 2 ⅐2H 2 O 2.5 mM), and oxygenated with 92.5% O 2 and 7.5% CO 2 . All animal protocols used were approved by the Animal Care and Use Committees of the Louis Stokes VA Medical Center and Case Western Reserve University. Hearts were perfused for 15 min before 25 min of global 37°C stop-flow ischemia, followed by 30 min reperfusion (2) . Left ventricular systolic pressure, diastolic pressure, developed pressure, and positive and negative dP/dt were measured (2). Coronary flow was measured every 5 min by timed collection of effluents and lactate dehydrogenase (LDH) activity assayed (2) . Total LDH release during reperfusion was computed as the area under the curve using the parallelogram method based on LDH release (mU/min LDH release ϫ ml/min coronary flow) computed at 5 min intervals during reperfusion (2).
Acetylcarnitine was administered by i.p. injection (300 mg/kg total dose, 125 mg/ml, neutralized to pH 6.0 -7.0 with NaOH). Three hours later the rats were euthanized and the heart removed for either isolation of mitochondria or isolated heart perfusion experiments. Control rats were either untreated (all 6 months and two 24 months) or received i.p. normal saline at pH 6.0 -7.0 (three 24 months) in an identical fashion to treated rats. Hemodynamic parameters, including recovery following ischemia, were similar in untreated and i.p. saline vehicle-treated aged hearts (untreated: 32%, 18%; saline treated: 30%, 19%, 20%).
SSM and IFM populations of cardiac mitochondria were isolated as described previously (12, 13, 16) . IFM were isolated by incubation of skinned myofibers, obtained after polytron treatment, with 5 mg/g (wet wt) trypsin for 10 min at 4°C. Oxygen consumption by intact mitochondria during state 3 and state 4 respiration was measured in a chamber equipped with a Clark type oxygen electrode (Yellow Springs Instrument Co., Yellow Springs, OH, USA) at 30°C (13) . Uncoupled respiration was measured in the presence of dinitrophenol (0.3 mM) (13, 14) . Electron transport complex III (decylubiquinol-cytochrome c reductase) was measured as described previously (9) . Mitochondrial cytochrome content was measured as the difference of reduced minus oxidized spectra (9, 13) . Samples for analysis of complex III and cytochromes were not available from all hearts. Differences between groups were compared by 1-way ANOVA (17) . A P Ͻ 0.05 was considered significant.
RESULTS
The protein yield of IFM was decreased in aged hearts as previously observed (13) . Acetylcarnitine did not alter the protein yield of IFM obtained from aged hearts. The yield of SSM was unaltered by age (Fig. 1) . The maximal rate of ADP-stimulated and dinitrophenol uncoupled oxidation was decreased in IFM from untreated aged hearts compared to untreated adult controls as described previously (13) . Treatment of aged rats with acetylcarnitine increased the maximal rate of oxidative phosphorylation in IFM to rates observed in the adult heart (Table 1, Fig. 1 ). Respiration in acetylcarnitine-treated aging hearts remained well coupled with unaltered state 4 respiration, respiratory control ratios, and ADP:O ratios (Table 1) .
Aging decreases the activity of complex III in IFM secondary to a defect at the quinol oxidation site with preserved content of subunit peptides, including cytochrome b (9, 10) . Acetylcarnitine treatment of aged rats restored the activity of complex III in IFM to that present in the adult heart ( Table 2) . Acetylcarnitine increased the content of cytochrome b in IFM (untreated aged: 0.24Ϯ0.01 nmol/mg protein, nϭ9 vs. acetylcarnitine-treated, aged 0.29Ϯ0.01, nϭ5, P Ͻ 0.05) as well as in SSM (untreated aged: 0.20Ϯ0.02 nmol/mg protein, nϭ9 vs. acetylcarnitine-treated, aged 0.32Ϯ0.01, Figure 1 . The protein content and rate of oxidative phosphorylation is decreased in interfibrillar mitochondria (IFM) from the 24 month Fischer 344 heart (aged, nϭ13) compared with 6 month controls (nϭ8), whereas subsarcolemmal mitochondria (SSM) remain unaltered by aging. Treatment of 24 month aged rats with acetylcarnitine (AcCN, nϭ6) (300 mg/kg by i.p. injection) 3 h before isolation of mitochondria from the aged heart did not alter the protein content of IFM but enhanced mitochondrial respiration in SSM and IFM. Ϯse; *P Ͻ 0.05 vs. same age control; # P Ͻ 0.05 vs. 6 months; Glut-glutamate; DHQ-durohydroquinone; TMPD/Asc-N,N,NЈ,NЈ tetramethyl p-phenylenediamine-ascorbate; respiratory rates expressed as nAO/mg protein/min using 2 mM ADP).
nϭ5, P Ͻ 0.05). Aging decreases respiration through cytochrome oxidase in intact IFM although cytochrome aa 3 content remains unchanged (9, 10, 13, 18) . Acetylcarnitine increased the content of cytochrome aa 3 in SSM (untreated aged: 0.62Ϯ0.03 nmol/mg protein, nϭ9 vs. acetylcarnitine-treated, aged 0.77Ϯ0.03, nϭ5, P Ͻ 0.05) without a significant increase in IFM (untreated aged: 0.69Ϯ0.02 nmol/mg protein, nϭ9 vs. acetylcarnitine-treated, aged 0.71Ϯ0.02, nϭ5, pϭNS).
Adult and aged hearts underwent 25 min of global ischemia followed by 30 min of reperfusion ( Table 3) . Acetylcarnitine treatment did not alter ventricular function measured before ischemia (Table 3) . Diastolic pressure at the end of ischemia was unaltered by acetylcarnitine in adult and aged hearts (Table 3) . Coronary flow before ischemia and during reperfusion was also unchanged by acetylcarnitine (Table 3 ). In the aged heart, acetylcarnitine enhanced the recovery of developed pressure ( Fig. 2 ) and positive and negative dP/dt (Table 3) , whether measured as absolute magnitude (Table 3) or as a percent of preischemic values (Fig. 2) . In contrast, in the adult heart contractile recovery during reperfusion was unchanged by acetylcarnitine treatment (Table 3 ). In acetylcarnitinetreated aged hearts, recovery was similar to the recovery of treated or untreated adult hearts.
Acetylcarnitine markedly reduced the release of LDH during reperfusion, a marker of myocyte necrosis, in the aged heart (Fig. 3) . In contrast, acetylcarnitine treatment did not alter LDH release during reperfusion in the adult heart (Fig. 3) . Thus, acetylcarnitine treatment of the aged heart before ischemia improved functional recovery and decreased myocyte cell death following ischemia and reperfusion.
DISCUSSION
Myocardial injury is increased in the aged heart following ischemia and reperfusion (1, (3) (4) (5) (6) . In the aged heart, IFM exhibit decreased protein yield and reduced rates of oxidative phosphorylation (13), complex III activity (9, 10), and respiration through complex IV (13) . Acetylcarnitine treatment restored the rate of oxidative phosphorylation in IFM from the aged heart whereas protein content remained decreased. Respiration remained tightly coupled after treatment with acetylcarnitine.
When the aged heart was exposed to ischemia and reperfusion after restoration of oxidative phosphorylation, there was less myocardial damage and improved contractile recovery. In contrast, acetylcarnitine treatment had no effect on the extent of myocardial damage or contractile recovery in the adult heart. Thus, acetylcarnitine did not alter mechanisms of ischemic damage common to both the adult and aged hearts. These observations provide strong support for the contribution of aging-related defects in mitochondrial oxidative metabolism to the enhanced damage after ischemia and reperfusion.
Aging decreases the maximal activity of complex III in IFM (9, 10) despite a preserved content of subunit peptides, including cytochrome b (9). The aging defect in complex III is located within the quinol oxidation domain of cytochrome b (10) . Acetylcarnitine restores complex III activity in IFM from aged hearts (Table 2) , accompanied by an increase in cytochrome b content. The increase in cytochrome b content following relief of the complex III enzyme defect is in line with cytochrome b as the locus of the aging defect. The increase in cytochrome b content observed in both SSM and IFM after treatment is consistent with an increase in mitochondrial transcription and protein synthesis, perhaps leading to an increased content of complex III, as discussed below.
Aging decreases the rate of oxidative phosphorylation stimulated by TMPD-ascorbate, an electron donor to cytochrome oxidase via cytochrome c in intact IFM (13) (Fig. 1) . Cytochrome oxidase activity measured in permeabilized mitochondria in the presence of exogenous cytochrome c remains decreased in IFM, localizing the defect to the oxidase. Aging did not alter the content of cytochrome aa 3 in IFM, indicating a preserved content of cytochrome oxidase (13) . The aging defect was overcome by the addition of exogenous phospholipid liposomes (13) or freezing-thawing combined with detergent solubilization (13) , interventions that alter the membrane environment of the complex.
Taken together, these findings strongly suggest that the aging decrease in cytochrome oxidase in IFM occurs due to an altered inner membrane environment of complex IV (8, 13) despite a preserved content of cardiolipin in IFM (8, 16) . Acetylcarnitine treatment improved respiration through cytochrome oxidase in both SSM and IFM (Fig. 1 ), consistent with previously described results (19) . Improvement appears to have occurred due increases in cytochrome aa 3 content, more prominent in SSM, with an increase in cytochrome oxidase content likely contributing to the enhanced TMPD-ascorbate stimulated respiration observed in SSM (Fig. 1 ). An acetylcarnitine-mediated improvement in the membrane environment of cytochrome oxidase in IFM that restored respiration in this mitochondrial population (13, 15, 20) would account for the restoration of the aging defect in IFM despite the absence of a marked increase in cytochrome aa 3 content.
Our working model for increased injury in the aged heart is that the addition of ischemia-induced defects on preexisting aging defects would enhance mitochondrial-derived myocyte injury in the aged heart (8) . Complex III is a major site of free radical production by mitochondria (21) (22) (23) (24) . Aging increases the production of reactive oxygen species (ROS) from complex III in IFM (10) . Myocardial ischemia damages complexes III (11, 25) and IV (14, 26) in the adult and aged heart (8) . Mitochondria produce ROS during ischemia (27) and also during reperfusion (28) . Complex III in IFM is a prime source for the enhanced production of ROS during ischemia or reperfusion (8, 24) .
Aging-induced decreases in complex IV activity in IFM should augment oxidant production. Relative blockage of electron flow through complex IV leads to increased reduction of upstream redox centers in complexes I and III (29) . The aging-induced decrease in respiration through complex IV in IFM (13, 15, 30) , coupled with additional decreases due to ischemic damage (14, 26), will predispose the aged heart to enhanced oxyradical production. It is reasonable to suppose that restoration of oxidative phosphorylation through complexes III and IV in interfibrillar mitochondria by acetylcarnitine (DHQ respiration, Fig. 1 ) would decrease oxidative damage during ischemia and reperfusion in the aged heart. Acetylcarnitine has been proposed to improve aging defects in electron transport by two mechanisms. First, acetylcarnitine was proposed to increase the content of cardiolipin (15, 19, 20) , a phospholipid present in mitochondria that is required for optimal activity of complex IV (31). However, despite the aging-related membrane defect in IFM (8, 13), aging does not decrease the content of cardiolipin in either SSM or IFM in the aged Fischer 344 rat heart (16) . Second, treatment with acetylcarnitine increases transcription of mitochondrial DNA (mtDNA) in the aged heart in a dose-and time-dependent manner (32) . The optimal response to acetylcarnitine occurs at 3 h and 300 mg/kg, the treatment regimen used in the current study. The content of mtRNA normalizes in the aged heart after treatment secondary to increased RNA synthesis (32, 33) . The increase in mtRNA synthesis leads to increased mitochondrial protein synthesis (chloramphenicol sensitive; ref 32) , with increased content of mitochondrial-encoded electron transport subunits after acetylcarnitine treatment (32) . Based on the increases seen in the contents of cytochrome aa 3 and b in the present study, it appears that stimulation of mitochondrial protein synthesis contributes to acetylcarnitine-mediated improvement in respiration in the aged heart.
In the current study, systemic administration of acetylcarnitine to the rat in vivo 3 h before ischemia protected the isolated heart subsequently exposed to in vitro ischemia and reperfusion. No additional drug was administered to the isolated heart. Direct in vitro administration of L-carnitine or propionyl-L-carnitine to isolated adult hearts reduced ischemic damage in some studies (34 -37), but not others (38, 39) . Consistent with these variable results, acetylcarnitine administered in vitro directly to the isolated adult heart had a minimal protective effect (37) . In vivo acetylcarnitine treatment does not increase the activity of electron transport chain enzymes in the adult heart (15, 20, 40) , further supporting the selective aging-related effect on mitochondrial function observed in the current study. Acetylcarnitine decreased the production of ROS and blunted cellular injury in the aged liver during ischemia and reperfusion (41) .
Despite successful and sustained reperfusion of the infarct zone, the mortality of acute myocardial infarction in elderly patients remained elevated 6-fold compared to middle-aged patients (6) . Although pharmacologic treatment at the onset of reperfusion can reduce myocardial injury (42, 43) , the option to use chronic pretreatment of high risk elders in a preemptive fashion before ischemia represents a novel cardioprotective strategy for the aged heart. The ability to modulate aging-induced defects in mitochondrial metabolism in order to reduce damage from ischemia and reperfusion is an attractive potential strategy to protect myocardium in the high-risk elderly patient suffering an acute myocardial infarction. 
SPECIFIC AIMS
Aging impairs mitochondrial oxidative metabolism in interfibrillar mitochondria (IFM) located between the myofibrils, with decreases in the rate of oxidative phosphorylation and decreased activity of electron transport complexes III and IV. The first aim of this study was to ask whether aging-induced defects in mitochondrial metabolism can be restored. The aged heart sustains greater damage during ischemia and reperfusion. The second aim of the study was to address the question, if the aging defects in mitochondrial respiration could be attenuated, would the aged heart now function as the adult heart and sustain less damage following ischemia and reperfusion?
PRINCIPAL FINDINGS

Acetylcarnitine treatment restores oxidative phosphorylation and complex III activity in IFM from the aged heart
Aging impairs cardiac mitochondrial metabolism, with decreases in the rate of oxidative phosphorylation and increased production of reactive oxygen species (ROS). Cardiac mitochondria exist in two functionally distinct populations. Subsarcolemmal mitochondria (SSM) lie beneath the plasma membrane. Interfibrillar mitochondria (IFM) are located between the myofibrils. Aging decreases oxidative phosphorylation and increases oxyradical production only in IFM, whereas SSM are unaffected. Aging decreases the activity of electron transport complexes III and IV in IFM. Treatment of aged rats with acetylcarnitine increased the maximal rate of oxidative phosphorylation in IFM to rates observed in the adult heart (glutamate respiration: 6 month Fischer 344 adult: 287Ϯ19 nAO/ min/mg protein, nϭ8, Ϯse; 24 month Fischer 344 aged 221Ϯ10, nϭ13, PϽ0.05 vs. adult; 24 month acetylcarnitine-treated Fischer 344 aged 307Ϯ15 nϭ6, pϭNS vs. adult, PϽ0.05 vs. untreated aged). Respiration in acetylcarnitine-treated aging hearts remained well coupled with unaltered state 4 respiration, respiratory control ratios, and ADP:O ratios.
Aging decreased the activity of complex III in IFM. Acetylcarnitine treatment of aged rats restored the activity of complex III in IFM to that present in the adult heart (adult: 4860Ϯ290 mU/min/mg protein, nϭ8; 24 month aged 4040Ϯ480, nϭ11; 24 month acetylcarnitine-treated aged 6250Ϯ870 nϭ5, pϭNS vs. 
Restoration of aging defects in IFM decreases ischemia-reperfusion injury in the aged heart
Adult and aged hearts underwent 25 min of global ischemia, followed by 30 min of reperfusion. Acetylcarnitine treatment did not alter ventricular function measured before ischemia. Diastolic pressure at the end of ischemia was unaltered by acetylcarnitine in adult and aged hearts. In the aged heart, acetylcarnitine enhanced the recovery of developed pressure (Fig.  1 ) and positive and negative dp/dt. In the adult heart, contractile recovery during reperfusion was unchanged by acetylcarnitine (Fig. 1) . In acetylcarnitine-treated aged hearts, recovery was similar to the recovery of treated or untreated adult hearts. Acetylcarnitine markedly reduced the release of lactate dehydrogenase (LDH) during reperfusion, a marker of myocyte necrosis, in the aged heart (Fig. 2) . In contrast, acetylcarnitine treatment did not alter LDH release during reperfusion in the adult heart (Fig. 2) . Thus, acetylcarnitine treatment of the aged heart before ischemia improved functional recovery and decreased myocyte cell death following ischemia and reperfusion.
CONCLUSIONS AND SIGNIFICANCE
Myocardial injury is increased in the aged heart following ischemia and reperfusion. In the aged heart, IFM exhibit decreased protein yield and reduced rates of oxidative phosphorylation, complex III activity, and respiration through complex IV. Acetylcarnitine treatment restored oxidative phosphorylation in IFM from the aged heart whereas protein content remained decreased. Respiration remained tightly coupled after treatment with acetylcarnitine. When the aged heart was exposed to ischemia and reperfusion after restoration of oxidative phosphorylation, there was less myocardial damage and improved contractile recovery. In contrast, acetylcarnitine treatment had no effect on the extent of myocardial damage or contractile recovery in the adult heart. Thus, acetylcarnitine did not alter mechanisms of ischemic damage common to both the adult and aged hearts. These observations provide strong support for the contribution of aging-related defects in mitochondrial oxidative metabolism to the enhanced damage following ischemia and reperfusion.
Aging decreased the maximal activity of complex III in IFM despite a preserved content of subunit peptides, including cytochrome b. The aging defect in complex III is located within the quinol oxidation domain of cytochrome b. Acetylcarnitine restored complex III activity in IFM from aged hearts, accompanied by an increase in cytochrome b content. The increase in cytochrome b content following relief of the complex III enzyme defect is in line with cytochrome b as the locus of the aging defect. Increased cytochrome b content observed in both SSM and IFM after treatment is consistent with an increase in mitochondrial transcription and protein synthesis, perhaps leading to an increased content of complex III.
Aging decreased the rate of oxidative phosphorylation stimulated by TMPD-ascorbate, an electron donor to cytochrome oxidase via cytochrome c in intact IFM. Acetylcarnitine treatment improved respiration through cytochrome oxidase in both SSM and IFM, consistent with previous results from other investigators.
In the aged heart, ischemia-induced defects in mitochondrial electron transport are superimposed on aging defects. Aging increases the production of ROS from complex III in IFM. Ischemia damages complexes III and IV in the adult and aged heart. Mitochondria produce ROS during ischemia and also during reperfusion. Complex III in IFM is a prime source for the enhanced production of ROS during ischemia or reperfusion. Relative blockage of electron flow through complex IV augments oxyradical production from up- Figure 3 . Treatment of 24 month aged rats with acetylcarnitine (AcCN) 3 h before isolation of mitochondria from the aged heart restored complex III activity in IFM and the rate of oxidative phosphorylation through complexes III and IV in the distal electron transport chain in interfibrillar mitochondria, the subpopulation of cardiac mitochondria altered by aging. Restoration of oxidative phosphorylation in the aged heart leads to improved functional recovery and decreased tissue injury following ischemia and reperfusion. stream redox centers. Thus, restoration of oxidative phosphorylation through complexes III and IV in interfibrillar mitochondria by acetylcarnitine treatment should decrease oxidative damage during ischemia and reperfusion in the aged heart. Acetylcarnitine may improve aging defects in electron transport by two potential mechanisms. First, acetylcarnitine may increase the content of cardiolipin, a phospholipid present in mitochondria that is required for optimal activity of complex IV. However, aging does not decrease the content of cardiolipin in either SSM or IFM in the aged Fischer 344 rat heart, making increased cardiolipin synthesis a less likely mechanism of protection. Second, treatment with acetylcarnitine has been shown to increase transcription of mitochondrial DNA in the aged heart in a dose-and time-dependent manner. The optimal response to acetylcarnitine occurred at 3 h and 300 mg/kg in the previous studies, the treatment regimen used in the current study. In the previous work, the content of mtRNA normalized in the aged heart after treatment secondary to increased RNA synthesis, which was accompanied by increased mitochondrial protein synthesis and an increased content of mitochondrial-encoded electron transport subunits after acetylcarnitine treatment. Based on the increases seen in the contents of cytochrome aa 3 and b in the present study, it appears that stimulation of mitochondrial protein synthesis is a potential mechanism of acetylcarnitine-mediated improvement in respiration in the aged heart. Future studies are required to explore whether acetylcarnitine increases cardiolipin content or, what is more likely, the synthesis of new electron transport complex III. If accumulation of aging induced oxidative damage to cytochrome b decreases complex III activity during aging, then a newly synthesized complex III would likely exhibit a nonaged phenotype.
In the current study, systemic administration of acetylcarnitine to the rat in vivo 3 h before ischemia protected the isolated heart subsequently exposed to in vitro ischemia and reperfusion. No additional drug was administered to the isolated heart. Thus, pretreatment of aging defects in the animal rendered the aged heart relatively resistant to ischemic injury without additional treatment of the heart in vitro. Previous studies found that acetylcarnitine administered in vitro directly to the isolated adult heart had a minimal protective effect. These studies also found that in vivo acetylcarnitine treatment did not increase the activity of electron transport chain enzymes in the adult heart, further supporting the selective aging-related effect observed in the current study.
Despite successful and sustained reperfusion of the infarct zone, the mortality of acute myocardial infarction in elderly patients remains elevated 6-fold compared to middle-aged patients. Although pharmacologic treatment at the onset of reperfusion can reduce myocardial injury, the option to utilize chronic pretreatment of high risk elders in a preemptive fashion before ischemia represents a novel cardioprotective strategy for the aged heart. The ability to modulate aging-induced defects in mitochondrial metabolism in order to reduce damage from ischemia and reperfusion is an attractive potential strategy to protect myocardium in the high-risk elderly patient.
